We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

9 hedge funds and large institutions have $3.42M invested in Provention Bio, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
9
Holders Change
+9
Holders Change %
–
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$2.82M
2
DIM
DC Investments Management
Virginia
+$162K
3
HighTower Advisors
HighTower Advisors
Illinois
+$139K
4
Goldman Sachs
Goldman Sachs
New York
+$86.6K
5
BlackRock
BlackRock
New York
+$82.1K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$2.86M +$2.82M +712,902 New
DIM
2
DC Investments Management
Virginia
$164K +$162K +40,950 New
HighTower Advisors
3
HighTower Advisors
Illinois
$141K +$139K +35,047 New
Goldman Sachs
4
Goldman Sachs
New York
$88K +$86.6K +21,900 New
BlackRock
5
BlackRock
New York
$84K +$82.1K +20,763 New
BCM
6
BlueCrest Capital Management
Jersey
$45K +$44.6K +11,294 New
TRCT
7
Tower Research Capital (TRC)
New York
$21K +$20.4K +5,172 New
UBS Group
8
UBS Group
Switzerland
$11K +$11.3K +2,850 New
Morgan Stanley
9
Morgan Stanley
New York
$2K +$2.11K +534 New

PRVB Hedge Fund Activity: Q3 2018 in Review

9 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2018, worth a combined $3.42M.

Buyers outnumbered sellers: 9 funds opened new PRVB positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $2.82M.

  • 9 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2018, up from 0 in Q2 2018.
  • Funds reported $3.42M of Provention Bio, Inc. Common Stock stock for Q3 2018.
  • 9 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2018 and 0 closed out, a net change of +9 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q3 2018 was Vanguard Group, an estimated $2.82M added.

Based on aggregated 13F filings for Q3 2018.